Phosphodiesterase inhibitors Lecture notes and 119 Scholarly Published articles free access

Drugs for Heart Failure
Drugs for Heart Failure.ppt

G-Protein membrane receptors
G-Protein membrane receptors.ppt

Viagra
Otega Edukuye
Viagra.ppt

Congestive Heart Failure
Chris Hague, PhD
Congestive Heart Failure.ppt

Positive Inotropic Agents
Pharmacology-Positive-PositiveInotropicAgentsfixed.ppt

The G Protein Pathway in Neuroscience
Henry Lester
The G Protein Pathway in Neuroscience.ppt

Dalteparin Pharmacodynamics/Mechanism of Action
Akash Bhakta
Dalteparin Pharmacodynamics/Mechanism of Action.ppt

Drugs for Heart Failure
Drugs for Heart Failure.ppt

Vision
vision.ppt

What is Heart Failure?
What is Heart Failure.ppt

Hemodynamic Disorders: Hemostasis Thrombogenesis: Platelet, Endothelial And Clotting Factor Interactions
Arthur S. Schneider, M.D
schneider-thrombosis_1112.ppt

Viagra and the Neonate
Robert E. Lyle, M.D.
Viagra and the Neonate.ppt

Antihypertensives, Diuretics, Anticoagulants and Dyslipidemics
Linda Self
Antihypertensives, Diuretics, Anticoagulants and Dyslipidemics.ppt

Medical Complications of Substance Abuse
Phil Green MD, Vishal Madaan, MD
Medical Complications of Substance Abuse.ppt

Drug Targets: Receptors
Drug Targets: Receptors.ppt

Pharmacologic Management of Acute Circulatory Failure: Vasoactive Medications
Suanne Daves, MD
Pharmacologic Management of Acute Circulatory Failure.ppt

Heart Failure and Antidysrhythmics
Linda Self
Heart_Failure_and_Antidysrhythmics.ppt

Drug Classes Cardiovascular Agents
Drug Classes Cardiovascular Agents.ppt

Review of Anticoagulants, Thrombolytics and Anti-platelet Drugs
Review of Anticoagulants, Thrombolytics and Anti-platelet Drugs.ppt

Pharmacology Review of Everything
Pharmacology Review of Everything.ppt

Xanomeline M1/M4 agonist
Xanomeline M1/M4 agonist.ppt

119 Scholarly Published articles free access

1. Phosphodiesterase Inhibitors Suppress Lactobacillus casei Cell-Wall-Induced NF-κB and MAPK Activations and Cell Proliferation through Protein Kinase A-or Exchange Protein Activated by cAMP-Dependent Signal Pathway.
2. Modulation of Th1/Th2 cytokine production by selective and nonselective phosphodiesterase inhibitors administered to mice.
3. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model.
4. Is there a place for treatment with type 5 phosphodiesterase inhibitors in heart failure patients?.
5. Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite.
6. cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases.
7. Phosphodiesterase inhibitors in vascular ischemia: A case report and review of their use in ischemic conditions.
8. Modulating effects of nonselective and selective phosphodiesterase inhibitors on lymphocyte subsets and humoral immune response in mice.
9. Phosphodiesterase inhibitors for pulmonary hypertension.
10. Effects of various selective phosphodiesterase inhibitors on relaxation and cyclic nucleotide contents in porcine iris sphincter.
11. Probing the catalytic sites and activation mechanism of photoreceptor phosphodiesterase using radiolabeled phosphodiesterase inhibitors.
12. Postulated vasoactive neuropeptide immunopathology affecting the blood-brain/blood-spinal barrier in certain neuropsychiatric fatigue-related conditions: A role for phosphodiesterase inhibitors in treatment?
13. Chronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors.
14. Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats.
15. Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.
16. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.
17. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension.
18. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors.
19. Administration of phosphodiesterase inhibitors and an adenosine A1 receptor antagonist induces phrenic nerve recovery in high cervical spinal cord injured rats.
20. Erectile dysfunction: treatment with type 5 phosphodiesterase inhibitors.
21. Regulation of intestinal hPepT1 (SLC15A1) activity by phosphodiesterase inhibitors is via inhibition of NHE3 (SLC9A3).
22. Protective effects of phosphodiesterase inhibitors on lung function and remodeling in a murine model of chronic asthma.
23. Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension.
24. Phosphodiesterase inhibitors.
25. The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery.
26. Effects of various selective phosphodiesterase inhibitors on carbachol-induced contraction and cyclic nucleotide contents in the guinea pig gall bladder.
27. Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors.
28. Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors.
29. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.
30. An interventional approach to block brain damage caused by Shiga toxin-producing Escherichia coli infection, by use of a combination of phosphodiesterase inhibitors.
31. Severe digital ischaemia treated with phosphodiesterase inhibitors.
32. Effects of various selective phosphodiesterase inhibitors on carbachol-induced contraction and cyclic nucleotide contents in guinea pig taenia coli.
33. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling.
34. Effects of phosphodiesterase inhibitors on interleukin-4 and interleukin-13 generation from human basophils.
35. EMD273316 & EMD95833, type 4 phosphodiesterase inhibitors, stimulate fibroblastic-colony formation by bone marrow cells via direct inhibition of PDE4 and the induction of endogenous prostaglandin synthesis.
36. The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma.
37. Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells.
38. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells.
39. Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors.
40. Effect of phosphodiesterase inhibitors on nitric oxide production by glial cells.
41. Molecular docking of competitive phosphodiesterase inhibitors.
42. Effect of type 3 and type 4 phosphodiesterase inhibitors on the maintenance of bovine oocytes in meiotic arrest.
43. Differential effect of phosphodiesterase inhibitors on IL-13 release from peripheral blood mononuclear cells.
44. Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity.
45. Randomized trial of phosphodiesterase inhibitors versus catecholamines in patients with acutely decompensated heart failure.
46. A sensitive assay of human blood platelet cyclic nucleotide phosphodiesterase activity by HPLC using fluorescence derivatization and its application to assessment of cyclic nucleotide phosphodiesterase inhibitors.
47. Effects of the specific phosphodiesterase inhibitors on alloxan-induced diabetic rabbit cavernous tissue in vitro.
48. The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways.
49. Comparison of phosphodiesterase inhibitors of differing isoenzyme selectivity added to St. Thomas' hospital cardioplegic solution used for hypothermic preservation of rat lungs.
50. Type 4 phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced airway hyper-responsiveness and lung eosinophilia.
51. Interaction of L-arginine and phosphodiesterase inhibitors in vasodilation of the porcine internal mammary artery.
52. Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension.
53. Phosphodiesterase inhibitors prevent NSAID enteropathy independently of effects on TNF-alpha release.
54. Anti-spasmogenic activity of isoenzyme-selective phosphodiesterase inhibitors in guinea-pig trachealis.
55. Effects of phosphodiesterase inhibitors after coronary artery bypass grafting.
56. Selective phosphodiesterase inhibitors modulate the activity of alveolar macrophages from sensitized guinea-pigs.
57. Enhancement of motility and acrosome reaction in human spermatozoa: differential activation by type-specific phosphodiesterase inhibitors.
58. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice.
59. Attenuation by phosphodiesterase inhibitors of lipopolysaccharide-induced thromboxane release and bronchoconstriction in rat lungs.
60. Effect of selective phosphodiesterase inhibitors on response of ovine pulmonary arteries to prostaglandin E2.
61. Effects of various selective phosphodiesterase inhibitors on muscle contractility in guinea pig ileal longitudinal smooth muscle.
62. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors.
63. Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
64. Stimulation of the hypothalamo-pituitary-adrenal axis in the rat by three selective type-4 phosphodiesterase inhibitors: in vitro and in vivo studies.
65. Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function.
66. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
67. Protection from T cell-mediated murine liver failure by phosphodiesterase inhibitors.
68. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
69. Phosphodiesterase inhibitors: Lily the Pink's medicinal compound for asthma?
70. The in vitro effects of phosphodiesterase inhibitors on the human internal mammary artery.
71. Phosphodiesterase inhibitors correct resistance to natriuretic peptides in rats with Heymann Nephritis.
72. Inhibition of the transendothelial migration of human lymphocytes but not monocytes by phosphodiesterase inhibitors.
73. Effect of phosphodiesterase inhibitors on human arteries in vitro.
74. Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen-induced cytokine gene expression in peripheral blood mononuclear cells.
75. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity.
76. Effects of phosphodiesterase inhibitors on spontaneous electrical activity (slow waves) in the guinea-pig gastric muscle.
77. Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma.
78. Theophylline and phosphodiesterase inhibitors.
79. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions.
80. Acute versus chronic administration of phosphodiesterase inhibitors on allergen-induced pulmonary cell influx in sensitized guinea-pigs.
81. A quantitative comparison of functional and anti-ischaemic effects of the phosphodiesterase-inhibitors, amrinone, milrinone and levosimendan in rabbit isolated hearts.
82. Relaxation of guinea-pig trachea by cyclic AMP phosphodiesterase inhibitors and their enhancement by sodium nitroprusside.
83. Prevention by phosphodiesterase inhibitors of antigen-induced contraction of guinea-pig colonic smooth muscle.
84. Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes.
85. Metabolic products of microorganisms. 268. Obscurolides, a novel class of phosphodiesterase inhibitors from streptomyces. II. Minor components belonging to the obscurolide B to D series.
86. Incomplete reversal of beta-adrenoceptor desensitization in human and guinea-pig cardiomyocytes by cyclic nucleotide phosphodiesterase inhibitors.
87. The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages.
88. Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses.
89. Metabolic products of microorganisms. 261. Obscurolides, a novel class of phosphodiesterase inhibitors from streptomyces. I. Production, isolation, structural elucidation and biological activity of obscurolides A1 to A4.
90. Differential regulation of TNF-alpha and IL-1beta production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors.
91. Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors.
92. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.
93. The effects of 16,16-dimethyl PGE2 and phosphodiesterase inhibitors on Con A blastogenic responses and NK cytotoxic activity of mouse spleen cells.
94. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells.
95. Inotropic responses to isoproterenol and phosphodiesterase inhibitors in intact guinea pig hearts: comparison of cyclic AMP levels and phosphorylation of sarcoplasmic reticulum and myofibrillar proteins.
96. Resensitization of hepatocyte glucagon-stimulated adenylate cyclase can be inhibited when cyclic AMP phosphodiesterase inhibitors are used to elevate intracellular cyclic AMP concentrations to supraphysiological values.
97. Effects of phosphodiesterase inhibitors on normal and chemically-skinned isolated airway smooth muscle.
98. Steroid-induced final maturation in brook trout (Salvelinus fontinalis) oocytes in vitro: the effects of forskolin and phosphodiesterase inhibitors.
99. Rolipram as a discriminative stimuli: transfer to phosphodiesterase inhibitors.
100. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors.
101. The influence of phosphodiesterase inhibitors on ERG and optic nerve response of the cat.
102. The effects of phosphodiesterase inhibitors and lanthanum ions on the light-sensitive current of toad retinal rods.
103. Effects of synthesized phosphodiesterase inhibitors, DM 9278 and HWA 285, on pancreatic exocrine secretion of the dog.
104. Effects of adenylate cyclase inhibitors, phosphodiesterase inhibitors, and dibutyryl cyclic AMP on spontaneous and various stimuli-induced acetylcholine release from guinea pig ileum myenteric plexus.
105. The effect of phosphodiesterase inhibitors on the electrical activity of toad rods.
106. Antagonism between steady light and phosphodiesterase inhibitors on the kinetics of rod photoresponses.
107. Effects of cyclic AMP- and cyclic GMP- phosphodiesterase inhibitors on immunological release of histamine and on lung contraction.
108. Phagocytosis of outer segments by cultured rat pigment epithelium. Reduction by cyclic AMP and phosphodiesterase inhibitors.
109. Effects of mammalian LH, cyclic AMP and phosphodiesterase inhibitors on steroidogenesis, lactate production, glucose uptake and utilization by avian granulosa cells.
110. Modulation of cellular interactions between C3H/10T1/2 cells and their transformed counterparts by phosphodiesterase inhibitors.
111. A model to test the relative potencies of phosphodiesterase inhibitors in brain (in vivo) proceedings.
112. Phosphodiesterase inhibitors: their comparative effectiveness in vitro in various organs.
113. Proceedings: Effects of dibutyryl cyclic AMP and phosphodiesterase inhibitors on acid secretion by mouse stomach in vitro.
114. Induction of motility in immature bovine spermatozoa by cyclic AMP phosphodiesterase inhibitors and seminal plasma.
115. Proceedings: The effect of phosphodiesterase inhibitors on the stimulation of cerebral cyclic AMP formation by biogenic amines in vitro and in vivo.
116. The effects of cyclic nucleotide phosphodiesterase inhibitors on ejaculated porcine spermatozoan metabolism.
117. The stimulation of bovine epididymal sperm metabolism by cyclic nucleotide phosphodiesterase inhibitors.
118. The effects of some phosphodiesterase inhibitors on the conductance of the perfused vascular beds of the chloralosed cat.
119. Interaction between phosphodiesterase inhibitors and catecholamines on contractions of the cat soleus muscle.